Sex: Female7116 (49.0%)–5524 (49.6%)16,751 (42.4%)–6917 (39.0%)5574 (62.4%)–2925 (61.5%)3054 (61.1%)–2548 (58.0%)1914 (32.3%)–1554 (30.9%)95 (0.77%)–96 (0.96%)6644 (33.9%)–3637 (30.0%)5108 (58.6%)–3896 (56.7%)46,256 (40.4%)–27,097 (37.6%)Male7417 (51.0%)–5621 (50.4%)22,779 (57.6%)–10,832 (61.0%)3363 (37.6%)–1832 (38.5%)1948 (38.9%)–1845 (42.0%)4015 (67.7%)–3477 (69.1%)12,175 (99.2%)–9928 (99.0%)12,957 (66.1%)–8485 (70.0%)3606 (41.4%)–2974 (43.3%)68,260 (59.6%)–44,994 (62.4%)Patients with Multimorbidity:14,533 (100%)–11,145 (100%)39,524 (100.0%)–17,734 (99.9%)8937 (100%)–4757 (100%)5002 (100%)–4393 (100%)5929 (100%)–5031 (100%)122,70 (100%)–10,024 (100%)19,601 (100%)–12,122 (100%)8714 (100%)–6870 (100%)114,510 (100.0%)–72,076 (100.0%)Chronic
diseases number (median, IQR):8.00 [7.00; 10.0]–10.0 [8.00; 12.0]7.00 [6.00; 9.00]–9.00 [7.00; 10.0]10.0 [8.00; 11.0]–11.0 [9.00; 13.0]11.0 [9.00; 13.0]–13.0 [11.0; 15.0]11.0 [9.00; 13.0]–13.0 [11.0; 15.0]9.00 [7.00; 11.0]–11.0 [9.00; 13.0]9.00 [8.00; 11.0]–11.0 [9.00; 12.0]11.0 [9.00; 12.0]–12.0 [10.0; 14.0]9.00 [7.00; 11.0]–10.0 [9.00; 13.0]Patients with Polypharmacy:12,961 (89.2%)–10,003 (89.8%)25,588 (64.7%)–11,785 (66.4%)8546 (95.6%)–4516 (94.9%)4877 (97.5%)–4284 (97.5%)5646 (95.2%)–4848 (96.4%)10,840 (88.3%)–9043 (90.2%)19,013 (97.0%)–11,812 (97.4%)8117 (93.1%)–6425 (93.5%)95,588 (83.5%)–62,716 (87.0%)Drugs number (median, IQR):8.00 [6.00; 10.0]–8.00 [6.00; 10.0]6.00 [3.00; 8.00]–6.00 [4.00; 8.00]10.0 [7.00; 12.0]–9.00 [7.00; 11.0]11.0 [8.00; 13.0]–11.0 [9.00; 13.0]10.0 [8.00; 13.0]–10.0 [8.00; 13.0]8.00 [6.00; 11.0]–9.00 [6.00; 11.0]9.00 [7.00; 12.0]–10.0 [8.00; 12.0]9.00 [7.00; 12.0]–9.00 [7.00; 12.0]8.00 [6.00; 11.0]–8.00 [6.00; 11.0]Age (Mean, SD):76.3 (6.4)–75.2 (6.0)80.6 (7.5)–78.4 (7.2)84.3 (6.1)–82.1 (5.8)76.0 (6.2)–75.1 (5.9)80.6 (6.4)–78.8 (6.1)74.5 (6.5)–73.5 (6.0)77.0 (6.8)–75.6 (6.36)79.2 (6.7)–77.8 (6.4)78.8 (7.4)–76.8 (6.8)Age (n, %):         [65,70)2678 (18.4%)–2417 (21.7%)3931 (9.94%)–2615 (14.7%)150 (1.68%)–127 (2.67%)935 (18.7%)–983 (22.4%)352 (5.94%)– 429 (8.53%)3408 (27.8%)–3165 (31.6%)3304 (16.9%)–2571 (21.2%)859 (9.86%)–845 (12.3%)15,617 (13.6%)–13,152 (18.2%)        [70,80)7123 (49.0%)–5945 (53.3%)12,539 (31.7%)–6947 (39.1%)1714 (19.2%)–1382 (29.1%)2540 (50.8%)–2319 (52.8%)2138 (36.1%)–2237 (44.5%)6000 (48.9%)–5097 (50.8%)9046 (46.2%)–6113 (50.4%)3464 (39.8%)–3171 (46.2%)44,564 (38.9%)–33,211 (46.1%)        [80,90)4498 (31.0%)–2710 (24.3%)18,578 (47.0%)–7212 (40.6%)5356 (59.9%)–2830 (59.5%)1480 (29.6%)–1073 (24.4%)3011 (50.8%)–2195 (43.6%)2685 (21.9%)–1713 (17.1%)6690 (34.1%)–3289 (27.1%)3897 (44.7%)–2671 (38.9%)46,195 (40.3%)–23,693 (32.9%)        [90,99]234 (1.61%)–73 (0.66%)4482 (11.3%)–975 (5.49%)1717 (19.2%)–418 (8.79%)47 (0.94%)–18 (0.41%)428 (7.22%)–170 (3.38%)177 (1.44%)–49 (0.49%)561 (2.86%)–149 (1.23%)494 (5.67%)–183 (2.66%)8140 (7.11%)–2035 (2.82%)MEDEA *:         R2961 (22.6%)–2228 (20.6%)7996 (23.0%)–3406 (19.9%)1955 (27.3%)– 980 (21.6%)764 (17.0%)–636 (15.0%)1141 (22.7%)–946 (19.3%)1866 (16.9%)–1461 (15.1%)3368 (19.1%)–2035 (17.3%)1507 (19.7%)–1164 (17.5%)21,558 (21.4%)–12,856 (18.4%)        U11974 (15.1%)–1706 (15.8%)5718 (16.5%)–2786 (16.3%)1255 (17.5%)–824 (18.2%)489 (10.9%)–490 (11.5%)722 (14.4%)–744 (15.2%)1558 (14.1%)–1409 (14.5%)2487 (14.1%)–1690 (14.3%)1188 (15.5%)–1066 (16.1%)15,391 (15.3%)–10,715 (15.4%)        U22100 (16.0%)–1797 (16.6%)5412 (15.6%)–2793 (16.3%)1093 (15.3%)–710 (15.7%)656 (14.6%)–633 (14.9%)701 (13.9%)–761 (15.6%)1714 (15.5%)–1565 (16.1%)2638 (15.0%)–1811 (15.4%)1176 (15.4%)–1089 (16.4%)15,490 (15.4%)–11,159 (16.0%)        U31983 (15.1%)–1668 (15.4%)5638 (16.2%)–2879 (16.8%)1048 (14.6%)–727 (16.1%)748 (16.7%)–738 (17.4%)761 (15.1%)–818 (16.7%)1797 (16.3%)–1609 (16.6%)2953 (16.8%)–2009 (17.0%)1225 (16.0%)–1092 (16.5%)16,153 (16.0%)– 11,540 (16.6%)        U42087 (15.9%)–1772 (16.4%)5203 (15.0%)–2774 (16.2%)948 (13.2%)–657 (14.5%)846 (18.8%)–797 (18.8%)833 (16.6%)–801 (16.4%)1978 (17.9%)–1783 (18.4%)3050 (17.3%)–2113 (17.9%)1248 (16.3%)–1105 (16.6%)16,193 (16.1%)–11,802 (16.9%)        U51999 (15.3%)–1631 (15.1%)4751 (13.7%)–2471 (14.4%)866 (12.1%)–631 (13.9%)989 (22.0%)–955 (22.5%)871 (17.3%)–823 (16.8%)2117 (19.2%)–1871 (19.3%)3107 (17.7%)–2133 (18.1%)1311 (17.1%)–1121 (16.9%)16,011 (15.9%)–11,636 (16.7%)N. of visits (median, IQR):25.0 [15.0; 35.0]–27.0 [18.0; 36.0]13.0 [7.00; 23.0]–13.0 [7.00; 23.0]17.0 [10.0; 29.0]–17.0 [8.00; 29.0]21.0 [13.0; 33.0]–22.0 [13.0; 35.0]24.0 [14.0; 37.0]–25.0 [14.0; 39.0]14.0 [9.00; 22.0]–15.0 [9.00; 23.0]16.0 [10.0; 26.0]–16.0 [10.0; 26.0]19.0 [11.0; 31.8]–20.0 [12.0; 33.0]17.0 [9.00; 28.0]–18.0 [10.0; 30.0]